Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Management of Diabetes Mellitus Patients With Retinopathy

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: January 23, 2009
Last updated: August 17, 2010
Last verified: August 2010

Aim of this NIS is to retrospectively document the management of diabetic patients with retinopathy in a naturalistic setting in Switzerland. Following elements are going to be analyzed:

  • which medication are used to keep blood pressure under control?
  • which medication are used for metabolic control?
  • the average control level of metabolism and blood pressure is compliant with the international guidelines?
  • laser photocoagulation plays a role in the control of metabolism and blood pressure?
  • there are differences in the control of metabolism and blood pressure between patients with DM I or DM II?
  • there is an influence of renal failure on the choose of medication?

Diabetes Mellitus

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: Management of Diabetes Mellitus Patients With Retinopathy

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Blood lipids, glycemia, HbA1C, blood creatinine, proteinuria, body weight [ Time Frame: every 3 months ]
  • evolution of diabetic retinopathy [ Time Frame: every 3 months ]

Secondary Outcome Measures:
  • concomitant medication [ Time Frame: every 3 months ]

Estimated Enrollment: 2500
Study Start Date: December 2008
Study Completion Date: August 2009
Diabetic patients with retinopathy


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Diabetic patients with diabetic retinopathy

Inclusion Criteria:

  • Diabetic patients
  • Diabetic retinopathy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00828425

  Show 62 Study Locations
Sponsors and Collaborators
  More Information

Responsible Party: Dr. Med. Dirk Schneider - Medical Director, AstraZeneca Pharmaceuticals Identifier: NCT00828425     History of Changes
Other Study ID Numbers: NIS-CCH-DUM-2008/1
Study First Received: January 23, 2009
Last Updated: August 17, 2010

Keywords provided by AstraZeneca:
Diabetes Mellitus
Management of diabetic patients with retinopathy

Additional relevant MeSH terms:
Diabetes Mellitus
Retinal Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Eye Diseases processed this record on May 25, 2017